- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06144385
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
December 27, 2023 updated by: Shanghai Ming Ju Biotechnology Co., Ltd.
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior systematic treatments.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tao Zhang, MD, PhD
- Phone Number: +86 027-85726375
- Email: 1277577866@qq.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Tao Zhang
-
Contact:
- Tao Zhang, MD, PhD
-
Principal Investigator:
- Tao Zhang, MD, PhD
-
Sub-Investigator:
- Jun Xue, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18-75 years-old, male or female
- Voluntarily willing to participate in the study and sign the written informed consent form
- Life expectation ≥12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1
- Histologically-confirmed hepatocellular carcinoma (HCC)
- No benefits from curative surgery or other local therapies are expected at screening, judged by investigators
- Radiologically-confirmed progression disease after at least one prior line of systematic treatment and limited benefits from current available options for hepatocellular carcinoma are expected at screening, judged by investigators
- Fresh samples or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained GPC-3 positive
- Per RECIST v1.1, at least one measurable lesion
- Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
- No active infections of hepatitis B virus
- Adequate organ functions
- Adequate venous access for apheresis
- Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy
- Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study
- Women of childbearing potential must have negative serum β-human chorionic gonadotropin (β-hCG) test result at screening and 48 hours prior to lymphodepletion
Exclusion Criteria:
- Active brain metastasis
- Primary lesion or infused lesions with the longest diameter ≥15 cm, or other potential risk which might not be appropriate for further study treatment judged by the investigator
- Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
- Systematic autoimmune disorders requiring long-term systematic immunosuppression
- Previously treated with any genetically engineered modified T-cell therapy nor other cell-gene therapy
- Active infections of hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis
- Uncontrolled or active infection at screening, prior to apheresis, 72 hours prior to lymphodepletion or 5 days prior to JWATM204 infusion
- With severe cardiovascular disease History or presence of clinically-relevant central nervous system (CNS) disorders
- With clinically-significant CNS disorders
- Current presence of or previously with hepatic encephalopathy
- ≥G2 hemorrhage within 30 days prior to screening, or in need of long-term anticoagulants
- Pregnant or lactating women
- Not satisfying pre-defined wash-out period for apheresis
- Received plasma exchange within 14 days prior to apheresis
- Unable or unwilling to comply with the study protocol, judged by the investigator, or other situations implying that the subject might not be appropriate to participate in the study
- Vaccinated with live vaccinations against infectious diseases within 8 weeks prior to JWATM204 infusion
- Previously allergic or intolerable to JWATM204 or its components
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-GPC3 T cells
The safety and efficacy of JWATM204 will be evaluated in a Bayesian Optimal Interval Design (BOIN) dose escalation approach.
3 CAR-T dose levels will be tested in this study: 1×10^8, 3×10^8, 10×10^8, and 30×10^8 CAR-T cells will be explored.
|
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWATM204 .
During JWATM204 production, subjects will receive a preconditioning chemotherapy regimen of cyclophosphamide and fludarabine to deplete the lymphocytes.
After lymphodepletion, subjects will receive single-dose treatment with JWATM204 by intravenous (IV) injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of dose-limiting toxicities (DLTs)
Time Frame: 28 days
|
Dose-limiting toxicity (DLT) is defined as an adverse event that occurred within 28 days after JWATM204 infusion that met any of the following criteria.
Any grade ≥3 nonhematologic toxicity associated with JWATM204 that has not resolved to ≤ grade 2 within 7 days, excluding clinically insignificant abnormalities in laboratory indicators Hematologic toxicity Grade ≥3 anaphylaxis Grade ≥3 infection did not resolve to grade ≤2 within 7 days after anti-infective treatment.
≥ grade 3 autoimmune toxicity during treatment Grade ≥3 cytokine release syndrome (CRS) during treatment that did not resolve to grade ≤2 within 72 hours.
Grade ≥3 CAR-T cell-associated encephalopathy syndrome/immune effector cell-associated neurotoxicity syndrome (CRES/ICANS) that did not resolve to grade ≤2 within 72 hours.
Grade 5 events of any nonmalignant cause.
|
28 days
|
Rate and severity of adverse events (AEs) and severe adverse events (SAEs)
Time Frame: 2 years
|
An AE is defined as any unfavorable and unintended sign, symptom, or disease (new or worsening) temporally associated with the use of study therapy, regardless of whether or not a causal relationship with the study therapy can be determined.
|
2 years
|
Rate and severity of clinically-significant abnormalities in laboratory testings
Time Frame: 2 years
|
Clinically-significant abnormalities in laboratory testings.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Copy number of the vector transgene of JWATM204 in peripheral blood
Time Frame: 1 year
|
The pharmacokinetic parameters of JWATM204 will be evaluated by quantitative polymerase chain reaction (qPCR) for the copy number of the vector transgene of JWATM204 in peripheral blood to evaluate T-cell expansion and persistence.
|
1 year
|
Objective response rate (ORR)
Time Frame: 2 years
|
Proportion of patients whose tumor volume has reached a predetermined value and can maintain a minimum time limit, including complete response and partial response patients.
|
2 years
|
Disease Control Rate (DCR)
Time Frame: 2 years
|
The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.
|
2 years
|
Progression-free survival (PFS)
Time Frame: 2 years
|
Defined as time from randomisation to first progression by investigator assessment using revised Response Evaluation Criteria in Solid Tumours (RECIST) guidelines (version 1.1) or death (by any cause in the absence of progression)
|
2 years
|
Overal survival (OS)
Time Frame: 2 years
|
Defined as the time from randomisation to death due to any cause.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tao Zhang, MD, PhD, Wuhan Union Hospital, China
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 24, 2022
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 15, 2023
First Submitted That Met QC Criteria
November 20, 2023
First Posted (Actual)
November 22, 2023
Study Record Updates
Last Update Posted (Estimated)
January 1, 2024
Last Update Submitted That Met QC Criteria
December 27, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JWATM204001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Carcinoma
-
Bristol-Myers SquibbActive, not recruitingHepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, AdultChile, Brazil, Argentina, China, Czechia, France, Hong Kong, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Singapore, Spain, Taiwan, Turkey
-
Queen's Medical CenterNational Cancer Institute (NCI)CompletedAdult Hepatocellular Carcinoma | Localized Resectable Adult Liver CarcinomaUnited States
-
Stanford UniversityCompletedHepatocellular Carcinoma | Liver Tumor | Liver Cancer | Liver CarcinomaUnited States
-
Wake Forest University Health SciencesTerminatedHepatocellular Carcinoma | Hepatoma | Liver Cell Carcinoma | Liver Cancer, Adult | Liver Cell Carcinoma, AdultUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Liver Cancer | Stage IVA Liver Cancer | Stage IVB Liver Cancer | Metastatic Liver CarcinomaUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular CarcinomaUnited States
-
Arbutus Biopharma CorporationCompletedHepatocellular Carcinoma | Hepatoma | Liver Cancer, Adult | Liver Cell Carcinoma, AdultUnited States, Taiwan, Singapore, China, Canada, Korea, Republic of
Clinical Trials on CAR-GPC3 T cells
-
Shenzhen University General HospitalRecruitingAdvanced Hepatocellular CarcinomaChina
-
Beijing Tsinghua Chang Gung HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.Suspended
-
RenJi HospitalCompleted
-
RenJi HospitalCARsgen Therapeutics Co., Ltd.CompletedHepatocellular CarcinomaChina
-
CARsgen Therapeutics Co., Ltd.RenJi Hospital; First Affiliated Hospital of Zhejiang University; NanJing PLA...Completed
-
Second Affiliated Hospital of Guangzhou Medical...First Affiliated Hospital, Sun Yat-Sen University; Guangdong Zhaotai InVivo... and other collaboratorsRecruitingHepatocellular Carcinoma | CAR | Immunotherapy | Squamous Cell Lung Cancer | GPC3 Gene Inactivation | T CellChina
-
Beijing Immunochina Medical Science & Technology...RecruitingHepatocellular Carcinoma , CholangiocarcinomaChina
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineNot yet recruitingHepatocellular Carcinoma | Liposarcoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Malignant Rhabdoid Tumor | Yolk Sac Tumor | Embryonal Sarcoma of LiverUnited States
-
RenJi HospitalRecruitingHepatocellular CarcinomaChina